共 27 条
- [3] Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (11):
- [5] Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
- [10] Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients [J]. SCIENTIFIC REPORTS, 2016, 6